PHAT
USDPhathom Pharmaceuticals Inc. Common Stock
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$12.920
고가
$13.320
저가
$12.310
거래량
0.84M
기업 기본 정보
시가총액
942.6M
산업
생명공학
국가
United States
거래 통계
평균 거래량
1.18M
거래소
NMS
통화
USD
52주 범위
관련 뉴스
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
First patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) --
HC Wainwright & Co. Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $26
HC Wainwright & Co. analyst Matthew Caufield maintains Phathom Pharmaceuticals with a Buy and raises the price target from $20 to $26.
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically meaningful
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)
관련 주식
KKRS
KKR Group Finance Co. IX LLC 4.625% Subordinated Notes due 2061
PNI
Pimco New York Municipal Income Fund II Common Shares of Beneficial Interest
IRTC
iRhythm Technologies Inc.
APD
Air Products and Chemicals Inc.
RGLS
Regulus Therapeutics Inc.
최신 정보 받기
가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기